- Home
- Companies
- Indee Labs
- Articles
Indee Labs articles
Developing a scalable and efficient transfection method is crucial in accelerating the discovery, development, and manufacturing of gene-modified cell therapies. Researchers need a reliable alternative that can rapidly and efficiently introduce nucleic acids, proteins and gene-editing complexes into cells for a variety of applications. However, current transfection methods such as electroporation have seen less success with transfection due to high toxicity a
Gene-modified cell therapies (GMCTs) represent the most effective therapeutic platform for many patients with advanced diseases including relapsed and refractory leukemia, non-Hodgkin lymphoma, and other blood cancers [1]. Specifically, chimeric antigen receptor T cell (CAR-T) therapies targeting CD19 have demonstrated remarkable responses and possibly cures in patients with advanced acute lymphoblastic leukemia (ALL) that were unresponsive to all prior therapies. Gene modified CAR-T ce
Ryan Pawell
Considerable investment into cancer research has led to the development of remarkable new therapies, which have greatly improved therapeutic outcome for the countless individuals diagnosed with cancer. Until recently, almost all therapies that were granted clinical approval were small molecules. However, biotechnological advances in the last several decades have made it possible to develop powerful new classes of therapeutics including macromolecules, nanoparticles, and even engineered cells.
Michael A. Evans
Ryan Pawell is the founder and CEO of Indee Labs, a Berkeley biotech. The mission of Indee Labs is to use microfluidic vortex shedding as a scalable method to deliver CRISPR reagents into cells for developing affordable cell and gene therapies in the future. In our previous blog post, we summarized the work from their latest publication on
Why do we need new cell contenders in the CAR field? Well, different CAR immune cells have different advantages and sometimes unique challenges or limitations.
So, we began our discussion of alternative CAR-cell types with CAR-NK cells due to their current standing as the most popular alternative CAR-based therapy. However, the expansion of CARs to other cell types has already begun and shows promising results. The utility of CAR endowe
Michael A. Evans